October 24, 2014
LABScreen® Multi is The Only FDA Cleared IVD Test for Detecting HNA-3
For many years, the transfusion medicine community has been concerned about transfusion related acute lung injury (TRALI*).
Several studies have been performed which have implicated the potential for antibodies to human leukocyte antigens (HLA) and human neutrophil antigens (HNA) to be involved in the mechanism for transfusion related acute lung injury (TRALI). Based on these results, multiple panels and groups have determined that testing for HLA, and if available HNA, antibodies would be beneficial to the blood supply and could possibly reduce the incidence of TRALI in patients.
In 2007, AABB began implementing a number of TRALI mitigation strategies for plasma and apheresis platelets. Most recently AABB Standard 184.108.40.206 was enacted, requiring centers that collect plasma and whole blood from potentially sensitized donors to screen for HLA antibodies.
An assay which can simultaneously screen for HLA and HNA antibodies will provide Blood Banks, Transfusion Services and Blood Centers with an efficient, cost-effective tool to implement TRALI risk reduction measures.
Screen multiple donors for HLA and HNA in one run with LABScreen Multi!
The LABScreen Multi assay is used to screen up to 96 donors for HLA and HNA all in one run. It’s easy to use, to interpret and, with the HLA Fusion™ software, data for both antigen groups is easy to analyze.
Compared to conventional testing methods for neutrophil antibodies, the LABScreen Multi assay offers an easy, efficient method for antibody screening.
Leveraging the Luminex® xMAP® technology, the LABScan™ 100 is used for data acquisition.
* This product is not associated with the diagnosis or treatment of TRALI.